Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02144272 | Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | PHASE1 | COMPLETED | 41 | — | — | Jun 1, 2014 | Jun 1, 2015 | Jul 17, 2015 | 4 | Bulgaria, Georgia +2 |
| Arm | Type | Description |
|---|---|---|
| LY3114062 (SC) | EXPERIMENTAL | LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg. |
| LY3114062 (IV) | EXPERIMENTAL | LY3114062 given once intravenous (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo (sodium chloride injection) given as a single SC dose. |
| Name | Type | Description |
|---|---|---|
| LY3114062 SC | DRUG | LY3114062 administered SC. |
| Placebo | DRUG | Placebo administered SC. |
| LY3114062 IV | DRUG | LY3114062 administered IV. |
Inclusion Criteria: * Signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening. * Presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms. Exclusion Criteria: * Synthetic disease-mod...